348 related articles for article (PubMed ID: 10953133)
1. Cytokine variations in patients with hormone treated prostate cancer.
Wise GJ; Marella VK; Talluri G; Shirazian D
J Urol; 2000 Sep; 164(3 Pt 1):722-5. PubMed ID: 10953133
[TBL] [Abstract][Full Text] [Related]
2. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer.
Drachenberg DE; Elgamal AA; Rowbotham R; Peterson M; Murphy GP
Prostate; 1999 Oct; 41(2):127-33. PubMed ID: 10477909
[TBL] [Abstract][Full Text] [Related]
3. Effect of luteinizing hormone-releasing hormone (LHRH) analogue treatment on a cytokine profile in prostate cancer patients.
Kaczmarek P; Pokoca L; Niemirowicz J; Majewska E; Baj Z
Pharmacol Rep; 2008; 60(3):399-403. PubMed ID: 18622065
[TBL] [Abstract][Full Text] [Related]
4. SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer.
Yu EY; Li H; Higano CS; Agarwal N; Pal SK; Alva A; Heath EI; Lam ET; Gupta S; Lilly MB; Inoue Y; Chi KN; Vogelzang NJ; Quinn DI; Cheng HH; Plymate SR; Hussain M; Tangen CM; Thompson IM
J Clin Oncol; 2015 May; 33(14):1601-8. PubMed ID: 25847934
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen induces proliferation of peripheral blood lymphocytes and cytokine secretion in benign prostate hypertrophy patients.
Zisman A; Lindner A; Zisman E; Lindner U; Mozes E
Eur Urol; 1999 Sep; 36(3):258-65. PubMed ID: 10450013
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic and prognostic significance of prostate specific antigen and serum interleukin 18 and 10 in patients with locally advanced prostate cancer: a prospective study.
Dwivedi S; Goel A; Natu SM; Mandhani A; Khattri S; Pant KK
Asian Pac J Cancer Prev; 2011; 12(7):1843-8. PubMed ID: 22126577
[TBL] [Abstract][Full Text] [Related]
8. [Prostatic specific antigen (PS), pro-inflammatory cytokines, and prostatic pathology (benign prostatic hyperplasia and cancer). Relationship with malignancy].
Cansino Alcaide JR; Vera San Martín R; Rodríguez de Bethencourt Codes F; Bouraoui Y; Rodríguez Berriguete G; Oueslati R; Pérez-Utrilla M; De la Peña Barthel J; Paniagua Gómez-Alvarez R; Royuela García M
Arch Esp Urol; 2009 Jun; 62(5):359-66. PubMed ID: 19721171
[TBL] [Abstract][Full Text] [Related]
9. In vitro modulation of tumor progression-associated properties of hormone refractory prostate carcinoma cell lines by cytokines.
Sokoloff MH; Tso CL; Kaboo R; Taneja S; Pang S; deKernion JB; Belldegrun AS
Cancer; 1996 May; 77(9):1862-72. PubMed ID: 8646686
[TBL] [Abstract][Full Text] [Related]
10. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
Miller N; Smolkin ME; Bissonette E; Theodorescu D
Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of serum soluble Fas level and its change during regression and progression of advanced prostate cancer.
Furuya Y; Nagakawa O; Fuse H
Endocr J; 2003 Oct; 50(5):629-33. PubMed ID: 14614220
[TBL] [Abstract][Full Text] [Related]
12. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer.
Miller JI; Ahmann FR; Drach GW; Emerson SS; Bottaccini MR
J Urol; 1992 Mar; 147(3 Pt 2):956-61. PubMed ID: 1371568
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of changes in prostate-specific markers after endocrine treatment of stage D2 prostatic cancer.
Matzkin H; Eber P; Todd B; van der Zwaag R; Soloway MS
Cancer; 1992 Nov; 70(9):2302-9. PubMed ID: 1382828
[TBL] [Abstract][Full Text] [Related]
14. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
15. [Prognostic factors for PSA relapse of prostate cancer after endocrine therapy].
Nakata S; Nakano K; Takahashi H; Shimizu K; Kawashima K
Nihon Hinyokika Gakkai Zasshi; 2005 Nov; 96(7):685-90. PubMed ID: 16363654
[TBL] [Abstract][Full Text] [Related]
16. Targeting FSH in androgen-independent prostate cancer: abarelix for prostate cancer progressing after orchiectomy.
Beer TM; Garzotto M; Eilers KM; Lemmon D; Wersinger EM
Urology; 2004 Feb; 63(2):342-7. PubMed ID: 14972486
[TBL] [Abstract][Full Text] [Related]
17. PSA evolution: a prognostic factor during treatment of advanced prostatic carcinoma with total androgen blockade. Data from a Belgian multicentric study of 546 patients.
Oosterlinck W; Mattelaer J; Casselman J; Van Velthoven R; Derde MP; Kaufman L
Acta Urol Belg; 1997 Oct; 65(3):63-71. PubMed ID: 9421938
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of changes in short-term prostate volume and serum prostate-specific antigen after androgen withdrawal in men with metastatic prostate cancer.
Furuya Y; Nagakawa O; Fuse H
Urol Int; 2003; 70(3):195-9. PubMed ID: 12660456
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.
Kwak C; Jeong SJ; Park MS; Lee E; Lee SE
J Urol; 2002 Sep; 168(3):995-1000. PubMed ID: 12187207
[TBL] [Abstract][Full Text] [Related]
20. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
D'Amico AV; Moul JW; Carroll PR; Cote K; Sun L; Lubeck D; Renshaw AA; Loffredo M; Chen MH
J Natl Cancer Inst; 2004 Apr; 96(7):509-15. PubMed ID: 15069112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
